For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Bone Morphogenetic Protein 9 (BMP-9), also known as growth differentiation factor 2 (GDF2), is a protein of the transforming growth factor beta superfamily. It contains an N-terminal TGF-beta-like pro-peptide (prodomain) (residues 56–257) and a C-terminal transforming growth factor beta superfamily domain (325–428). BMP-9 is expressed by nonparenchymal cells in the liver and secreted as a homodimer. It is involved in a number of physiologic events, including induction of orthotopic bone formation, glucose homeostasis, iron homeostasis and the inhibition of angiogenesis. Mutations in BMP-9 have been identified in patients with a vascular disorder phenotypically overlapping with hereditary hemorrhagic telangiectasia.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Protein|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||5,000 Assay Points|